Development of 1h mrs biomarkers for tracking early predementia Alzheimer disease

Kejal Kantarci, Gregory A. Jicha

Research output: Contribution to journalEditorial

6 Scopus citations
Original languageEnglish
Pages (from-to)209-210
Number of pages2
Issue number5
StatePublished - Jan 29 2019

Bibliographical note

Funding Information:
K. Kantarci serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc.; receives research support from Avid Radiopharmaceuticals and Eli Lilly; and is funded by the NIH (R01 AG040042 [PI], U01 NS100620 [PI], RF1 AG57547 [PI], U54 AG 44170/Project 2 [PI]) and the Alzheimer’s Drug Discovery Foundation. G. Jicha is funded by the NIH (R01 AG038651, R01 AG042419, R01 AG054130, P30 AG028383, R01 HD064993, R01 NR014189, UH2 NS100606, U19AG010483, UL1TR000117) and through contract research with AbbVie, Alltech, Biohaven, Esai, Janssen, Novartis, and Suven. Go to for full disclosures.

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Development of 1h mrs biomarkers for tracking early predementia Alzheimer disease'. Together they form a unique fingerprint.

Cite this